Connect with us

Cannabis News

Two federal courts hold cannabis capital raisers liable for securities fraud

Published

on











Raising capital in the cannabis industry comes with real legal risk, and two recent federal rulings drive home that point.

In Michigan, five investors known as the “5 Guys” sued after they wired $1.5 million for a stake in a Muskegon dispensary joint venture, only to realize they had diverted the money to cover the parent company’s payroll and operating costs instead of funding the business as promised. The defendants tried to defend themselves using the “unlawful contract” defense, arguing that because marijuana is federally illegal, courts should not enforce agreements related to it. Thus Chief Justice Y. Jarbou drew a distinction: claims that would seek to validate illegal enterprise, such as breach of fiduciary duty, were dismissed, but fraudulent claims survived, as ordering restitution for fraud is not the same as enforcing an illegal agreement. The Court has also declined to allow the reliance rebuttal standard to automatically eliminate allegations of fraud.

In California, the SEC’s case against American Patriot Brands — a former food truck company that got into cannabis and raised more than $50 million from investors — reached the penalty phase. Judge Anne Hwang ordered the company nearly $24 million, including more than $2.6 million for high salary and personal expenses to its CEO, plus permanent injunctions and two executive officers and directors.

Together, the rulings send a clear message: the legal gray area of ​​cannabis does not extend to fraud. Operators are advised to treat each raise as a securities offering, spend investors’ money as directed, fully disclose related party agreements and bring securities advice rather than surface issues.










Cannabis News

Federal Judge Questions Link Between Marijuana And Guns, Citing ‘Widespread State Legalization’

Published

on

By

“Our current presumption has the practical effect of depriving marijuana users … of their Fourth Amendment right against unreasonable searches and seizures.”

From the Carolina Journal

The newest member of the 4th U.S. Circuit Court of Appeals used a North Carolina case Wednesday to discuss the potential legal ramifications of changing its stance on marijuana.

Justice Nicole Berner offered her commentary in an eight-page concurring opinion in United States v. in Carson. Berner was nominated to the 4th Circuit in 2024 by then-President Joe Biden.

Appeals judges upheld Jermaine Derrick Carson Jr.’s conviction for being a felon in possession of a firearm. The court rejected Carson’s arguments that the evidence against him should be suppressed. It contained evidence from Asheville police detective Steven Escobedo’s search of Carson during a traffic stop.

Berner supported the majority decision. However, much of his consensus was devoted to the connection between marijuana and law enforcement pursuits.

“I agree with my colleagues that our precedent in United States v. Sakyi dictates the outcome of this case,” Berner wrote, citing a 1998 4th Circuit precedent.

“Sakyi created a presumption that a police officer has reasonable suspicion to search a suspect for a weapon during a traffic stop when he reasonably suspects that illegal drugs are in the car,” Berner explained. “Applying this binding precedent, we are left only to conclude that Escobedo did not violate Carson’s Fourth Amendment rights when he went to look for Carson’s weapons because Escobedo reasonably suspected that marijuana was in the car.”

“The Sakyi presumption is based on a simple premise: ‘where there are drugs, there are almost always guns,'” Berner wrote. “This premise that a person suspected of being near illegal drugs is believed to be carrying a gun can no longer hold in this era of widespread legalization of marijuana.”

“In the nearly thirty years since Sakyi was decided, the alleged link between marijuana use and gun ownership has weakened,” he added. “In fact, the Government admitted as much in oral arguments.”

“The legal landscape surrounding the use of marijuana, both medical and recreational, has changed significantly at both the state and federal levels,” Berner continued. “Forty-seven states and the District of Columbia currently allow the medical use of marijuana. Twenty-four states, including a number within the Fourth Circuit, have legalized the recreational use of marijuana. Although federal law continues to criminalize marijuana, the federal government has “largely allowed the production and sale of marijuana under state law, and has allowed marijuana businesses to develop.”

“Sakyi believes that people who use and distribute illegal drugs will carry weapons for protection,” Berner argued. “In the wake of changes in federal law and widespread state legalization, safety concerns are now absent for many marijuana users. A person in Maryland, for example, can walk into a dispensary and legally purchase marijuana without the need for the type of protection that Sakyi based its nexus analysis on.”

Berner highlighted the actions of Asheville police in Carson’s case.

“The facts of this case demonstrate an unassailable disconnect between marijuana use and dangerousness,” the judge wrote. “The officers themselves repeatedly assured Carson and the other occupants of the car that they ‘were not the weed police.’ In fact, even though marijuana remains illegal in North Carolina, the Asheville Police Department no longer charges people with possession of marijuana for personal use. This approach follows the lead of the Department of Justice, which ordered federal prosecutors to drop marijuana charges more than a decade ago.”

Government prosecutors are now in an “awkward position” to suggest that “the millions of Americans who now regularly use marijuana are dangerous,” Berner wrote. The recent Supreme Court decision in United States v. to Heman it emphasizes the need to revise our belief. There, the Court held unconstitutional a law criminalizing the possession of weapons that applied to occasional marijuana users.’

“The court expressly rejected the view that the link between dangerousness and marijuana use could be maintained given the evolving legal and social landscape,” the agreement continued. “However, under our circuit law, reasonable suspicion to search for weapons remains whenever a police officer detects the odor of marijuana.”

The 4th Circuit’s “view is contrary to the decisions of our sister circuits,” Berner argued. A three-judge 4th Circuit panel was unable to change that view.

“As a result, Sakyi connects us, and I agree with my colleagues in their specific opinion,” Berner. he wrote. “I write separately to emphasize that our current presumption has the practical effect of denying those who use marijuana, even in states where it has been legalized under state law, as well as those who find themselves in close proximity to others who use marijuana, their Fourth Amendment right against unreasonable searches and seizures.”

“As marijuana laws and social mores continue to evolve, this presumption may not survive constitutional scrutiny,” Berner added.

This story was first published by the Carolina Journal.

Photo elements courtesy of the user rawpixel and Philip Steffan.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Tilray Medical announces commercial launch of medical cannabis in Panama

Published

on

By

Tilray Medical has announced the launch of its first medical cannabis product in Panama, part of the company’s continued global expansion and commitment to improving patient access to pharmaceutical grade cannabinoids worldwide.

Following the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP certified production facilities in Portugal through a joint venture with Solana Life Group S. de RL, the Product is to be distributed through Farmacias Arrocha, one of the leading pharmaceutical chains in Panama, where patients will be able to access Tilray Oral Solution CBD with medical prescription100. This is expected to provide patients and healthcare professionals with access to regulated medical cannabis of pharmaceutical quality through established healthcare channels.

Rajnish Ohri, International President, Tilray Brands, said: “At Tilray Medical, we believe that every patient deserves access to safe, consistent, pharmaceutical-grade cannabis products. The launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines around the world. We want pharmacists and patients to help shape the future of responsible access, advance medical education and provide high-quality treatment options that improve lives.”

The launch supports the Panamanian medical cannabis framework established by Law 242 of 2021 and follows important regulatory advances made by the Ministry of Health, including No. 0406 of May 12, 2026. The decision, which established the main conditions for the admission of patients. The Ministry also recently introduced the System for the Identification of Medical Cannabis Users and Authorized Caregivers (SIUCMAA), creating a structured way to authorize medical practitioners and register patients.

Manufactured in Portugal under strict European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use in patients with qualified medical conditions permitted under Panamanian law, where permitted. The products reflect Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety and regulatory compliance.

Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP certified medical cannabis products to regulated markets worldwide. The platform enables Tilray Medical to effectively support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.

For more information:
Tilray
www.tilray.com

Continue Reading

Cannabis News

Medical Marijuana Is ‘Effective’ In Providing Relief To Patients With Restless Legs Syndrome, Study Shows

Published

on

By

People with restless leg syndrome (RLS) may find “significant” long-term relief with cannabis treatment, according to a new study.

While dopamine agonists have traditionally been the “first-line treatment” for RLS, recent studies indicate that gabapentinoids are now being recommended, the researchers said. Because cannabinoids, like gabapentinoids, inhibit a certain type of amino acid associated with the disorder, scientists decided to test their therapeutic effectiveness.

The open-label exploratory study, conducted by European researchers at the University of Madrid and published in the Journal of Neurology, found that a cannabis product containing 2.7 mg of THC and 2.5 mg of CBD was “effective in reducing RLS severity” among patients with multiple sclerosis and “associated idiopathic RLS.”

“Improvements were observed after 1 to 3 months of treatment and were maintained after 1 year among patients who continued therapy,” the study of 18 patients with RLS showed. For those who remained in treatment after a year, 67 percent “continued to show sustained improvement.”

The the findings it may not be surprising that cannabis in particular is known to reduce the severity of muscle spasms and related conditions, but its effectiveness for RLS is remarkable given that no state specifically lists it as a condition for medical cannabis.

Of course, RLS can be a symptom of other general disorders like multiple sclerosis, and some states give doctors more latitude to make recommendations for medical marijuana for any condition they see fit.

In any case, research outside of Spain could be based on research into alternative treatment options that could replace dopamine agonists in the treatment of restless legs syndrome.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media